While children under five, particularly those under two, are the most vulnerable, pneumococcal diseases also affect adults.

The American Academy of Pediatrics (AAP) has assembled nearly 200 stories and dozens of testimonials on the horrors of ...

The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of efforts to protect infants ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Vaxcyte's new pneumococcal vaccine may only have phase ... A phase 2 study in children will also start early in 2025. Buoyed by the new data, Vaxcyte – which had almost $1.9 billion in cash ...

The ACIP-approved immunization schedules for children and adolescents and for adults for 2025 have been published.

Children under the age of two are particularly vulnerable to pneumococcal infection, and incidence of invasive pneumococcal disease remains highest in the first year of life, according to Merck.

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...